Thrivent Financial for Lutherans Buys 21,548 Shares of Stryker Corporation $SYK

Thrivent Financial for Lutherans boosted its stake in shares of Stryker Corporation (NYSE:SYK) by 22.1% during the fourth quarter, Holdings Channel reports. The firm owned 119,191 shares of the medical technology company’s stock after purchasing an additional 21,548 shares during the quarter. Thrivent Financial for Lutherans’ holdings in Stryker were worth $41,905,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also added to or reduced their stakes in the business. VanderPol Investments L.L.C. grew its holdings in shares of Stryker by 1.4% during the 4th quarter. VanderPol Investments L.L.C. now owns 2,084 shares of the medical technology company’s stock worth $732,000 after purchasing an additional 28 shares during the period. Lantz Financial LLC grew its holdings in shares of Stryker by 5.0% during the 3rd quarter. Lantz Financial LLC now owns 608 shares of the medical technology company’s stock worth $225,000 after purchasing an additional 29 shares during the period. Stonebridge Capital Advisors LLC grew its holdings in shares of Stryker by 0.4% during the 3rd quarter. Stonebridge Capital Advisors LLC now owns 7,198 shares of the medical technology company’s stock worth $2,661,000 after purchasing an additional 29 shares during the period. Tcfg Wealth Management LLC grew its holdings in shares of Stryker by 2.7% during the 3rd quarter. Tcfg Wealth Management LLC now owns 1,091 shares of the medical technology company’s stock worth $403,000 after purchasing an additional 29 shares during the period. Finally, Sompo Asset Management Co. Ltd. grew its holdings in shares of Stryker by 1.3% during the 2nd quarter. Sompo Asset Management Co. Ltd. now owns 2,390 shares of the medical technology company’s stock worth $946,000 after purchasing an additional 30 shares during the period. 77.09% of the stock is currently owned by institutional investors.

Stryker Stock Up 0.4%

NYSE SYK opened at $306.74 on Friday. The stock has a market cap of $117.59 billion, a PE ratio of 35.50, a P/E/G ratio of 1.93 and a beta of 0.80. Stryker Corporation has a fifty-two week low of $281.00 and a fifty-two week high of $404.87. The business has a 50 day moving average price of $329.68 and a two-hundred day moving average price of $351.73. The company has a quick ratio of 1.25, a current ratio of 2.11 and a debt-to-equity ratio of 0.62.

Stryker (NYSE:SYK) last released its quarterly earnings results on Thursday, April 30th. The medical technology company reported $2.60 earnings per share for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.38). The company had revenue of $6.02 billion during the quarter, compared to analysts’ expectations of $6.34 billion. Stryker had a return on equity of 23.42% and a net margin of 13.20%.The firm’s revenue was up 2.6% compared to the same quarter last year. During the same quarter in the prior year, the company earned $2.84 EPS. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. As a group, sell-side analysts predict that Stryker Corporation will post 14.98 EPS for the current fiscal year.

Stryker Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, July 31st. Investors of record on Tuesday, June 30th will be paid a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.1%. The ex-dividend date is Tuesday, June 30th. Stryker’s payout ratio is 40.74%.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on SYK shares. Deutsche Bank Aktiengesellschaft set a $315.00 target price on Stryker in a report on Friday, May 1st. UBS Group decreased their target price on Stryker from $400.00 to $380.00 and set a “neutral” rating for the company in a report on Tuesday, March 17th. Citigroup decreased their price target on Stryker from $420.00 to $385.00 and set a “buy” rating for the company in a report on Tuesday, April 7th. Barclays decreased their price target on Stryker from $469.00 to $394.00 and set an “overweight” rating for the company in a report on Monday, May 4th. Finally, Leerink Partners began coverage on Stryker in a report on Monday, April 13th. They issued an “outperform” rating and a $410.00 price target for the company. Sixteen analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $395.48.

Insider Activity

In related news, VP M Kathryn Fink sold 3,500 shares of Stryker stock in a transaction on Monday, May 11th. The shares were sold at an average price of $283.45, for a total value of $992,075.00. Following the completion of the sale, the vice president owned 177 shares in the company, valued at approximately $50,170.65. The trade was a 95.19% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 4.60% of the company’s stock.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.